Navigation Links
Quanterix Announces New Technology Evaluation Agreement
Date:2/22/2011

CAMBRIDGE, Mass., Feb. 22, 2011 /PRNewswire/ -- Quanterix Corporation, enabling a new generation of diagnostic tests based on revolutionary Single Molecule Array (SiMoA™) technology, today announced that it has entered into an evaluation agreement with Novartis Diagnostics on the potential use of Quanterix's SiMoA platform technology for diagnostic use.  The evaluation will be conducted at Quanterix and will focus on an undisclosed neuron-specific protein target.

"We are excited to initiate this technology evaluation with Novartis, one of the world's leading healthcare companies," said David Okrongly, Ph.D., Quanterix President and Chief Executive Officer.  "This partnership is an important milestone for Quanterix, and another step toward our goal to be the recognized global leader in sensitive and precise detection technology.  Through this collaborative project, we hope to leverage the 1000-fold sensitivity improvement of SiMoA technology to develop a novel class of valuable diagnostic tests that will provide greater insight into disease and improve patient outcomes."

About Quanterix

Quanterix Corporation is developing its proprietary Single Molecule Array (SiMoA™) technology for the in vitro diagnostics and life science research markets. The digital nature of SiMoA yields unprecedented assay performance, stemming from a 1,000-fold improvement in sensitivity compared with today's analog only technology.  SiMoA will enable researchers in life science to validate novel, low abundance biomolecules from a single droplet of blood, leading to greater insight into disease detection, diagnosis, therapy selection and disease monitoring.  Automated systems based on SiMoA are being designed to provide diagnostic test information to healthcare practitioners faster, with greater reliability, unprecedented range and increased cost effectiveness.  Founded in 2007, the privately held Cambridge, Massachusetts-based company is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures.  For additional information, please visit www.quanterix.com.


'/>"/>
SOURCE Quanterix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Quanterix Corporation Announces the Addition of Dr. Robert Corn to its Scientific Advisory Board
2. Stereotaxis Announces Election of Joseph D. Keegan to Board of Directors
3. China Cord Blood Corporation Announces Results of 2010 Annual General Meeting
4. Dendreon Announces Presentation of PROVENGE Data at the 2011 Genitourinary Cancers Symposium Annual Meeting
5. Sensus Healthcare Announces Its Exhibitor Attendance at the 9th Annual South Beach Symposium™
6. Sensus Healthcare Announces the Formation of a Medical Advisory Board
7. Sigma-Aldrich Announces Organizational Changes
8. Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
9. MiMedx Announces Launch of AmnioFix™
10. Savient Pharmaceuticals Announces Executive Appointments
11. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , ... October 12, 2017 ... ... has launched Rosalind™, the first-ever genomics analysis platform specifically designed for life ... Named in honor of pioneering researcher Rosalind Franklin, who made a major ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... pathology, announced today it will be hosting a Webinar titled, “Pathology is going ... Pathology Associates , on digital pathology adoption best practices and how Proscia improves ...
(Date:10/11/2017)... Florida (PRWEB) , ... October 11, 2017 , ... ... Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 ... for the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane ...
(Date:10/10/2017)... 2017 International research firm Parks Associates announced today ... the TMA 2017 Annual Meeting , October 11 in ... home security market and how smart safety and security products impact the ... Parks Associates: Smart Home Devices: ... "The residential security market has experienced ...
Breaking Biology Technology:
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
(Date:3/28/2017)... India , March 28, 2017 ... IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software ... Vertical, and Region - Global Forecast to 2022", published ... Billion in 2016 and is projected to reach USD ... between 2017 and 2022. The base year considered for ...
(Date:3/24/2017)... , March 24, 2017 The Controller General of ... Mr. Abdulla Algeen have received the prestigious international IAIR Award ... Continue Reading ... ... and Deputy Controller Abdulla Algeen (small picture on the right) have received ...
Breaking Biology News(10 mins):